Heat Biologics is a clinical-stage company focused on developing its proprietary "ImPACT" (Immune Pan-Antigen Cytotoxic Therapy) fully allogeneic "off-the-shelf" cell based immunotherapy to treat patients with a wide array of cancers and infectious diseases.
November 8, 2017 - November 12, 2017
Society for Immunotherapy of Cancer (SITC) 2017 Annual Meeting
October 17, 2017 - October 18, 2017
BIO Investor Forum
Heat Biologics’ proprietary ImPACT technology transforms allogenic living cells into miniature osmotic pumps that continually secrete heat shock protein gp96, the most potent mammalian adjuvant ever described, along with its chaperoned antigens.
